6533b86cfe1ef96bd12c834f
RESEARCH PRODUCT
The Nasal Epithelium as a Factory for Systemic Protein Delivery
Eric W.f.w. AltonPeter K. JefferyUta GriesenbachDuncan M. GeddesMamoru HasegawaRobin L. CassadyMasayuki FukumuraJie ZhuStefano FerrariChristian MüllerYoshiyuki NagaiEdgar Schmittsubject
virusesGenetic enhancementmedicine.medical_treatmentMucous membrane of noseSendai virus03 medical and health sciences0302 clinical medicineIn vivoDrug DiscoverymedicineGeneticsAnimalsHumansMuscle SkeletalLungMolecular BiologyNose030304 developmental biologyPharmacology0303 health sciencesLungbiologyGene Transfer TechniquesSkeletal musclerespiratory systembiology.organism_classificationSendai virus3. Good healthInterleukin-10Nasal Mucosamedicine.anatomical_structureCytokine030220 oncology & carcinogenesisImmunologyCOS CellsMolecular MedicineHeLa Cellsdescription
We have previously shown that recombinant Sendai virus (SeV) produces efficient in vivo airway epithelial gene transfer. The ability to produce therapeutic levels of circulating proteins following noninvasive gene transfer would have widespread clinical application. Here, we compared nose, lung, and skeletal muscle for the ability to produce circulating levels of the secreted mouse antiinflammatory cytokine interleukin-10 (IL10) following SeV-mediated gene transfer. High levels of serum IL10 were obtained from each site with a potency order of lung > nose > muscle for a given viral titer. Serum levels from each site were within the likely required range for anti-inflammatory effects. The combination of a high-efficiency gene transfer agent (SeV) and sites that can be assessed noninvasively (nose or lung) may circumvent several current challenges to gene therapy.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2002-02-01 | Molecular Therapy |